Welcome : Guest

BioMarin Pharmaceutical, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about BioMarin Pharmaceutical, Inc., which is principally involved in Pharmaceuticals Business. Illustrated with 24 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-63866
Price: $1200
Company Type: Public
Pages: 27
Date: November 2016
Market Data Tables: 24

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: BioMarin Pharmaceutical, Inc.’s (Operations) Sales by Product Segment Worldwide (2014-2015) in Percentage for Vimizim, Naglazyme, Kuvan, Aldurazyme, and Firdapse......3
Table 2: BioMarin Pharmaceutical, Inc.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, Europe, Latin America, and Rest of World......4
Table 3: Biomarin Pharmaceutical, Inc.’s (Operations) Sales by Product Segment Worldwide (2013-2014) in Percentage for Naglazyme, Kuvan, Aldurazyme and Others......5
Table 4: Biomarin Pharmaceutical, Inc.’s Sales by Geographic Region Worldwide (2013-2014) in Percentage for United States, Europe, Latin America and Rest of World......6
Hemophilia......8
Table 5: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......8
Table 6: Hemophilia Diagnosis and Treatments Rates by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Diagonised, Pristine Joints, Prophylactic, Treated, and Others......9
Table 7: Haemophilia by Severity Stage Worldwide (2015) - Percentage Market Share Breakdown by No. of Patients for Mild, Moderate and Severe......10
Table 8: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......11
Table 9: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......12
Table 10: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......13
Table 11: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......14
Table 12: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......15
Table 13: Haemophilia B - Recombinant (Benefix) Sales by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Emerging Markets, Europe, US, and Others......16
Table 14: Immune Tolerance Therapy (Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......17
Table 15: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......18
Table 16: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......19
Table 17: U.S. Hemophilia Market Patients Treated/Year (2014)......20
Genetic Testing......21
Table 18: Genetic Testing Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Detection, Predisposition, Treatment Selection, Monitoring, and Others......21
Table 19: Genetic Testing Market by Category in the US (2015) - Percentage Share Breakdown by Volume for Cancer, Neurology, Pediatric Development, and Others......22
Table 20: Genetic Test Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Exome, Mendeliome, Small Panel, and Whole Genome......23
Gene Therapy......24
Table 21: Gene Therapy Clinical Trials Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Phase I, n=1183, Phase I/II, n=384, Phase II, n=330, Phase II/III, n=20 and Phase III, n=74......24
Duchenne Muscular Dystrophy (DMD) Disease......25
Table 22: Duchenne Muscular Dystrophy (DMD) Disease Market by Therapy in the U.S (2015) - Percentage Breakdown by No. of Patients for Exon 44, Exon 45, Exon 46, Exon 51, Exon 53, and Others......25
Table 23: Duchenne Muscular Dystrophy (DMD) Disease Market by Therapy in European Union (2015) - Percentage Breakdown by No.of Patients for Exon 44, Exon 45, Exon 46, Exon 51, Exon 53, and Others......26
Β-Glucocerebrosidase......27
Table 24: Market Shares of Leading Βeta-Glucocerebrosidase Injection Brands in the US (2015) - Percentage Share Breakdown by Value for Cerezyme and Others......27